Clifford Swan Investment Counsel LLC Has $31.90 Million Holdings in AbbVie Inc. $ABBV

Clifford Swan Investment Counsel LLC trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 146,672 shares of the company’s stock after selling 1,971 shares during the period. AbbVie makes up 1.1% of Clifford Swan Investment Counsel LLC’s investment portfolio, making the stock its 25th largest holding. Clifford Swan Investment Counsel LLC’s holdings in AbbVie were worth $31,900,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Quadrant Private Wealth Management LLC increased its stake in shares of AbbVie by 9.1% in the 1st quarter. Quadrant Private Wealth Management LLC now owns 20,478 shares of the company’s stock valued at $4,454,000 after acquiring an additional 1,700 shares in the last quarter. Ranch Capital Advisors Inc. boosted its stake in AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after acquiring an additional 4,017 shares in the last quarter. Heartland Bank & Trust Co boosted its stake in AbbVie by 32.3% during the first quarter. Heartland Bank & Trust Co now owns 21,721 shares of the company’s stock worth $4,724,000 after acquiring an additional 5,308 shares in the last quarter. Zhang Financial LLC grew its holdings in AbbVie by 16.0% in the first quarter. Zhang Financial LLC now owns 33,927 shares of the company’s stock worth $7,379,000 after purchasing an additional 4,667 shares during the period. Finally, Atlas Wealth LLC bought a new stake in AbbVie in the first quarter valued at $31,419,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research reports. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. JPMorgan Chase & Co. raised their target price on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Canaccord Genuity Group upped their price target on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Guggenheim increased their price target on AbbVie from $249.00 to $261.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Finally, Citigroup increased their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $267.67.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

AbbVie Trading Up 0.1%

AbbVie stock opened at $254.53 on Friday. AbbVie Inc. has a 1-year low of $184.63 and a 1-year high of $261.64. The firm has a market capitalization of $449.70 billion, a price-to-earnings ratio of 125.38, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30. The firm’s fifty day moving average price is $229.80 and its two-hundred day moving average price is $221.94.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business’s revenue was up 12.4% on a year-over-year basis. During the same period last year, the company earned $2.46 earnings per share. On average, research analysts forecast that AbbVie Inc. will post 14.16 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s payout ratio is 340.89%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.